PHVS
Pharvaris N.V.
NASDAQ · NLHealthcareBiotechnology
$34.50-1.26%
Price as of Jul 20, 2026
PHVS ownership
Pharvaris N.V. ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
44
Net (3m)
-$11.4M
Insider trades by month Buys Sells
Apr
May
Jun
Jul
Context3-month price +18.1%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 14, 2026 | Lu Pengofficer: Chief Medical Officer | Tax | 109 | $35.07 |
| Jul 14, 2026 | Lu Pengofficer: Chief Medical Officer | Tax | 117 | $35.07 |
| Jul 1, 2026 | Schikan Johannes Gerardus Christiaan Petrusdirector | Sell | 6,888 | $35.05 |
| Jul 1, 2026 | Lesage Anneofficer: Chief Early Development | Sell | 6,997 | $35.05 |
| Jul 1, 2026 | Lesage Anneofficer: Chief Early Development | Sell | 30,703 | $35.49 |
| Jul 1, 2026 | Lesage Anneofficer: Chief Early Development | Sell | 27,872 | $35.48 |
| Jul 1, 2026 | Lesage Anneofficer: Chief Early Development | Option | 24,900 | $8.05 |
| Jul 1, 2026 | Lesage Anneofficer: Chief Early Development | Option | 2,972 | $2.59 |
| Jul 1, 2026 | Lesage Anneofficer: Chief Early Development | Sell | 8,300 | $35.05 |
| Jul 1, 2026 | Lesage Anneofficer: Chief Early Development | Sell | 2,300 | $35.12 |
| Jul 1, 2026 | Lesage Anneofficer: Chief Early Development | Option | 4,200 | $8.05 |
| Jul 1, 2026 | Lesage Anneofficer: Chief Early Development | Option | 4,100 | $2.59 |
| Jul 1, 2026 | Lesage Anneofficer: Chief Early Development | Option | 900 | $8.05 |
| Jul 1, 2026 | Lesage Anneofficer: Chief Early Development | Option | 1,400 | $2.59 |
| Jul 1, 2026 | Schikan Johannes Gerardus Christiaan Petrusdirector | Sell | 30,712 | $35.49 |
| Jun 29, 2026 | Schikan Johannes Gerardus Christiaan Petrusdirector | Sell | 2,400 | $35.10 |
| Jun 29, 2026 | Lu Pengofficer: Chief Medical Officer | Sell | 14,700 | $34.00 |
| Jun 29, 2026 | Lu Pengofficer: Chief Medical Officer | Option | 14,700 | $2.59 |
| Jun 29, 2026 | Lu Pengofficer: Chief Medical Officer | Sell | 3,400 | $35.09 |
| Jun 29, 2026 | Lu Pengofficer: Chief Medical Officer | Sell | 11,600 | $34.45 |
| Jun 29, 2026 | Lu Pengofficer: Chief Medical Officer | Option | 15,000 | $2.59 |
| Jun 29, 2026 | Lesage Anneofficer: Chief Early Development | Sell | 2,300 | $35.12 |
| Jun 29, 2026 | Lesage Anneofficer: Chief Early Development | Option | 900 | $8.05 |
| Jun 29, 2026 | Lesage Anneofficer: Chief Early Development | Option | 1,400 | $2.59 |
| Jun 23, 2026 | Lu Pengofficer: Chief Medical Officer | Sell | 300 | $34.00 |
| Jun 23, 2026 | Lu Pengofficer: Chief Medical Officer | Option | 300 | $2.59 |
| Jun 17, 2026 | Modig Berndtdirector, officer: Chief Executive Officer | Sell | 2,191 | $31.05 |
| Jun 17, 2026 | Modig Berndtdirector, officer: Chief Executive Officer | Sell | 100 | $31.46 |
| Jun 16, 2026 | Lu Pengofficer: Chief Medical Officer | Tax | 117 | $32.20 |
| Jun 15, 2026 | Lu Pengofficer: Chief Medical Officer | Tax | 109 | $31.51 |
Source: PHVS SEC Form 4 filings, latest Jul 14, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their PHVS positions over the last 6 months (SEC Form 13F).
Increased
80
New positions
40
Reduced
54
Sold out
13
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| GENERAL ATLANTIC, L.P. | Unchanged | 8.0M | Feb 17, 2026 |
| GENERAL ATLANTIC, L.P. | Unchanged | 8.0M | May 15, 2026 |
| FMR LLC | Unchanged | 6.4M | Feb 17, 2026 |
| FMR LLC | Reduced | 6.3M | May 15, 2026 |
| FORESITE CAPITAL MANAGEMENT IV, LLC | Unchanged | 4.8M | Feb 17, 2026 |
| FORESITE CAPITAL MANAGEMENT IV, LLC | Unchanged | 4.8M | May 15, 2026 |
| VENBIO PARTNERS LLC | Unchanged | 4.6M | May 15, 2026 |
| VENBIO PARTNERS LLC | Unchanged | 4.6M | Feb 17, 2026 |
| VIKING GLOBAL INVESTORS LP | Unchanged | 3.7M | Feb 17, 2026 |
| VIKING GLOBAL INVESTORS LP | Unchanged | 3.7M | May 15, 2026 |
| EQT FUND MANAGEMENT S.A R.L. | Unchanged | 3.4M | May 14, 2026 |
| EQT FUND MANAGEMENT S.A R.L. | Unchanged | 3.4M | Feb 11, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Increased | 3.1M | Feb 17, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Unchanged | 3.1M | May 15, 2026 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | Reduced | 2.8M | Feb 17, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.